W ith over 1500 scientists and 24 patents granted, the Cipla’s R&D focus is towards developing complex and innovative products. In the past two years, Cipla has stepped up R&D investments targeting the US, with several assets such as gAdvair, gProventil and gAbraxane in the pipeline. The R&D investments for FY2018 was Rs 10.74 billion corresponding to 7.1 per cent of revenue.
The company plans to enhance its API R&D and
manufacturing capacities in therapeutic areas such as Respiratory and Oncology and conduct backward integration for manufacturing of Key Starting Materials (KSMs) and critical API intermediates to gain a spot at the forefront.
The R&D investment on Respiratory is slated to increase from 12 per cent of the total R&D investments of the company in FY18 to above 30 per cent for the next year.
Key Highlights – FY2018 11 products launched in the US; these include products such as Budesonide Respules, Decitabine Injection and complex products like Sevelamar Launched Minispacer, Multihaler 60 and Synchrobreathe Respiratory devices in India along with 19 other products Imatinib 400 mg Tablets and Nifedipine XR tablets 30, 60 mg launched in SA
16 products introduced in Europe, which include 10 respiratory products
22 products launched in international markets, which include 14 respiratory products 7 products were launched under the Cipla Global Access (CGA) programme
24 US ANDAs filed, including 7 NCE-1s
5 dossiers submitted to DCGI, India
First product filed in Brazil (Imatinib tablets)
First CTA filed for China (FPSM)
16 dossiers submitted for SAGA (10 South Africa + 6 CGA)
3 products filed in Europe
4 products filed in Australia
4 pre-IND submissions to USFDA